Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement, In Brief

Executive Summary

Berwick confirmation hearing preview: In May 12 remarks on the Senate floor, Republican senators roll out criticism that Centers for Medicare and Medicaid Services Administrator-nominee Donald Berwick is a proponent of health care rationing, a theme the minority is likely to take up at Berwick's not-yet-scheduled confirmation hearing in the Senate Finance Committee. The White House officially nominated Berwick, who is founder and CEO of the Institute for Healthcare Improvement, on April 19 (1"The Pink Sheet," April 26, 2010). Sen. Pat Roberts, R-Kan., charged that Berwick is philosophically aligned with the stringent cost containment applied by the British National Health Service, quoting Berwick as saying: "The NHS is not just a national treasure, it is a global treasure." Senate Minority Leader Mitch McConnell, R-Ky., said Berwick's position that the number of health care specialty services in metropolitan areas should be reduced will end up further limiting options for patients in rural areas. Roberts also stated that Berwick supports "age rationing" by advocating fewer medical procedures in end-of-life care. The health reform law will cost more than expected, Roberts said, and to control spending, "Dr. Berwick will be the man who cuts health care costs by putting the rationing plans into practice.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS052237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel